MOG and neoplasm: Researchers primed synNotch-CAR-T cells through a highly tumor-specific neoantigen such as EGFRvIII, or a tissue-specific antigen such as myelin oligodendrocyte glycoprotein (MOG) in a GBM6 patient-derived xenograft model.